Grassley briefs Dems on outstanding FDA issues

Share this article:
Outgoing Senate Finance Committee chairman Chuck Grassley (R-IA) has written Democrat Senate HELP Committee leaders with a laundry list of FDA shortcomings that he hopes they will address in the new session beginning in January. In a letter, he summarized “systemic” FDA problems, such as drug safety, scientific morale, and a “too cozy” relationship with the industries it regulates.

Grassley complained about FDA senior officials who “disregarded and downplayed important concerns and warnings from its own scientists,” and their pressures to have scientists change their findings or conclusions regarding a safety or efficacy issue.

The day after Grassley sent his letter, incoming HELP Committee chairman Edward M. Kennedy (D-MA) took the opportunity of the committee's last, lame-duck session to lambaste their impact on the FDA.

“Science has, too often, had to take a backseat at the very agency which should be setting the standard for objectivity and integrity,” he said.  

Share this article:

Email Newsletters

More in News

AstraZenca beefs up respiratory portfolio

AstraZenca beefs up respiratory portfolio

AstraZeneca has made an $875-million move to beef up its respiratory pipeline by making Almirall's lineup its own.

Amgen Q2 sales rise, company to lay off up to 2,900

Amgen Q2 sales rise, company to lay off ...

The majority of the layoffs will be in the US.

Doctors want to know how CMS plans to display Sunshine payment data

Doctors want to know how CMS plans to ...

Physician and industry trade groups are asking CMS to explain how context will be provided to the general public around the dollar sums drugmakers ascribe to doctors for things like ...